Jump to content

CUV - CLINUVEL PHARMACEUTICALS LIMITED


colaiscute

Recommended Posts

  • Replies 51.4k
  • Created
  • Last Reply

Top Posters In This Topic

  • royco

    2914

  • Kiwi1

    1702

  • seeva222

    1669

  • Reality Check

    1771

Top Posters In This Topic

Posted Images

Well, I didnÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢t know that Scenesse was in the process of being approved in Australia and Japan for EPP...
Link to comment
Share on other sites

The Clinuvel 2020 strategy has been upgraded to Clinuvel 2021ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚°ÃƒÆ’â€Â¦Ãƒƒâہ¡ÃƒÆ’‚¸ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’‚¾ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚°ÃƒÆ’â€Â¦Ãƒƒâہ¡ÃƒÆ’‚¸ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¤ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚£
Link to comment
Share on other sites

Someone here pointed out reporting obligations being reduced due to certain parameters being met (Frogster or ajshare?), which according to the AGM presentation is to occur in 2019. What effect does this have in general on share price performance, or other factors concerning the company? I would think that such a reduction in reporting would have minimal effect, but I am curious to know if historically there is more speculation from the market given it has less information at hand to work with.
Link to comment
Share on other sites

I'm just going through the presentation now and noticed something a little interesting. Did anyone notice the two small pictures of a spray and a cream on page 26 in relation to "world's first locoregional photoprotection"?

 

They could just be pictures for the sake of putting something there, or they could be showing that the 2 forthcoming products cuv9900 and vlrx001, one is a spray and one is a cream.

 

What other crumbs can we find.

Link to comment
Share on other sites

The FDA has already stated that Scenesse does not cause cancer. UV light causes skin cancer. Looking back at what dermatologist where saying more than a decade ago their argument against afamelanotide was that it could cause moles to become cancerous. Dermatologists are no longer using that false storyline and in fact, dermatology in the UK is now saying Scenesse should be funded for the treatment of EPP. The NICE disagreement is with the Scenesse pricing. No gripe whatsoever about Dr WallyÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s fake tanning issue.

Going back to this, the AGM presentation pointed out why people use to think that Scenesse could cause skin cancer. It says Scenesse darkens moles and freckles, and unusually dark moles can be cancer. But it also depends on irregularity, size, border, shape, etc. This is probably a regulatory concern because it could impact diagnosis if the moles are indeed darkening, even though it isn't causing cancer. The increased melanin could actually prevent the mole from becoming cancerous.

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×
×
  • Create New...